Department Of Neurooncology
Investigator
Andrew Lassman, MD
Phone
212-342-0571
Email
abl7@cumc.columbia.edu

Andrew B. Lassman, MD, is the John Harris Associate Professor of Neurology and the Chief of Neuro-oncology at Columbia University. After earning BS and MS degrees in Molecular Biophysics and Biochemistry as part of a combined 4-year program at Yale University, he received his MD from Columbia University College of Physicians and Surgeons. Dr. Lassman subsequently completed his residency at the Neurological Institute of NewYork-Presbyterian Hospital/Columbia University Medical Center, and fellowship in Neuro-Oncology at Memorial Sloan-Kettering Cancer Center, where he then joined the faculty and served as fellowship director.

In November 2011, Dr. Lassman became Chief of Neuro-Oncology at Columbia University Medical Center, and also serves as the Medical Director for the Clinical Protocol Data Management Office of the Herbert Irving Comprehensive Cancer Center.

Dr. Lassman received the Preuss Award in Neuro-Oncology from the American Academy of Neurology, the Boyer Clinical Research Award from Memorial Sloan-Kettering Cancer Center, and the Gary Lichtenstein Humanitarian Award from Voices Against Brain Cancer. His clinical practice is limited to central nervous system tumors and metastases.


Clinical Studies Managed By This Investigator:
Condition Study Title
Brain Tumors [ CLOSED ] A study for patients with newly-diagnosed Glioblastoma Multiforme using study drug Bortezomib
Breast Cancer [ CLOSED ] A study for patients with HER2 positive breast cancer using study drug Trastuzumab for treatment
Brain Tumors [ CLOSED ] A study for patients with glioblastoma using study drug ABT-414
Brain Tumors [ CLOSED ] Study for Patients with Anaplastic Astrocytoma That Progress/Recur After Radiation and Chemotherapy (Brain Tumors)
Brain Tumors [ CLOSED ] A study for patients with malignant glioblastoma or glioma using study drug PF-06840003
Brain Tumors [ CLOSED ] A study for patients with Glioblastoma using study drug Tesevatinib monotherapy
Brain Tumors [ CLOSED ] Study of the efficacy and safety of Selinexor (KPT-330) in patients with recurrent gliomas
Brain Tumors [ CLOSED ] Study of Radiotherapy with Adjuvant Drug versus Radiotherapy with PCV Chemotherapy in Patients with Glioma
Brain Tumors [ CLOSED ] Study of Treatment Effects in Subjects with Glioblastoma Multiforme (GBM) - Glioma, Brain Tumor
Brain Tumors Study of Vaccine for Cytomegalovirus (CMV) in Patients with Brain Tumor
Brain Tumors [ CLOSED ] Study of Drug BGB-290 in Patients with Glioblastoma
Brain Tumors [ CLOSED ] Study for Management of Eye Side Effects in Patients with EGFR-Amplified Glioblastoma Receiving ABT-414
Brain Tumors [ CLOSED ] REGAL- Recurrent Glioblastoma Treated with Selinexor and Temozolomide
Cancer [ CLOSED ] Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging
Brain Tumors Study of ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Brain Tumors [ CLOSED ] Study of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of Epidermal Growth Factor Receptor (EGFR)
Brain Tumors Study to Evaluate Multiple Treatments for Patients with Newly Diagnosed or Recurrent GBM
Brain Tumors Study of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Brain Tumors A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Brain Cancer [ CLOSED ] Study for Patients with Anaplastic Astrocytoma That Progress/Recur After Radiation and Chemotherapy
Brain Cancer Study of ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Brain Cancer Study to Evaluate Multiple Treatments for Patients with Newly Diagnosed or Recurrent GBM
Brain Cancer Study of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Brain Cancer A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Brain Cancer Study of Vaccine for Cytomegalovirus (CMV) in Patients with Brain Tumor